Materiality pending
Public signal · 1-minute delayed
Signal brief
Source-backed market context you can read and share without an account.
AI summary
What happened, with direct paths to the underlying reporting
- TScan Therapeutics reported a quarterly loss of $0.32 per share, missing expectations. - Revenues for TScan were $0.57 million, significantly lower than anticipated. - TScan stock has gained 32.6% this year, outperforming the market. Price Impact Rating: Bearish Impact Horizon Rating: Short-term Type: Earnings
- TScan Therapeutics reported a quarterly loss of $0.32 per share, missing expectations.
- Revenues for TScan were $0.57 million, significantly lower than anticipated.
- TScan stock has gained 32.6% this year, outperforming the market.
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.